470-24 | Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

Overview

“A single-arm, open-label, prospective, multicenter safety study to evaluate the occurrence of essential fatty acid deficiency (EFAD) in pediatric patients with parenteral nutrition-associated cholestasis (PNAC) who require more than eight weeks of Omegaven treatment”

This study will demonstrate safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population.